Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes

Jinny Min, Stanley Cohan, Enrique Alvarez, Jacob Sloane, J. Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, Andrew Chan

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Introduction: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. Methods: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072). GI management strategies were assessed via a study site questionnaire. Discontinuation rates were analyzed according to counseling patterns. Results: Of 826 DMF-treated patients at 66 sites, 809 from 65 sites were eligible for the GI analysis; of these, 27% experienced GI AEs. Within 1 year of treatment, 14% (118/826) of patients discontinued DMF, 5% (44/809) due to GI events. Most sites (92%) reported that patients were very likely (> 75% of the time) to be counseled about GI events at/before DMF treatment initiation and/or to be recommended that DMF be taken with food (86%); 48% of sites reported to be very likely to recommend using symptomatic therapies for GI AEs. Lower discontinuation rates were reported at sites very likely versus not very likely (≤ 75% of the time) to (1) provide counseling; (2) provide specific details regarding GI events; or (3) recommend taking DMF with food, and/or using symptomatic GI therapies. Conclusion: Counseling and other GI management strategies at initiation of DMF treatment appear to reduce the burden of GI events, and a variety of GI management strategies may improve DMF persistence. Trial Registration: NCT02776072. Funding: Biogen (Cambridge, MA, USA).

Original languageEnglish
Pages (from-to)109-119
Number of pages11
JournalNeurology and Therapy
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Jun 2019
Externally publishedYes

Keywords

  • Gastrointestinal events
  • Multiple sclerosis
  • Retrospective study
  • Tecfidera

Cite this

Min, Jinny ; Cohan, Stanley ; Alvarez, Enrique ; Sloane, Jacob ; Phillips, J. Theodore ; van der Walt, Anneke ; Koulinska, Irene ; Fang, Fang ; Miller, Catherine ; Chan, Andrew. / Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis : Management Strategies to Improve Persistence on Treatment and Patient Outcomes. In: Neurology and Therapy. 2019 ; Vol. 8, No. 1. pp. 109-119.
@article{72579e5c59704db998152895c57aaf6e,
title = "Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes",
abstract = "Introduction: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. Methods: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072). GI management strategies were assessed via a study site questionnaire. Discontinuation rates were analyzed according to counseling patterns. Results: Of 826 DMF-treated patients at 66 sites, 809 from 65 sites were eligible for the GI analysis; of these, 27{\%} experienced GI AEs. Within 1 year of treatment, 14{\%} (118/826) of patients discontinued DMF, 5{\%} (44/809) due to GI events. Most sites (92{\%}) reported that patients were very likely (> 75{\%} of the time) to be counseled about GI events at/before DMF treatment initiation and/or to be recommended that DMF be taken with food (86{\%}); 48{\%} of sites reported to be very likely to recommend using symptomatic therapies for GI AEs. Lower discontinuation rates were reported at sites very likely versus not very likely (≤ 75{\%} of the time) to (1) provide counseling; (2) provide specific details regarding GI events; or (3) recommend taking DMF with food, and/or using symptomatic GI therapies. Conclusion: Counseling and other GI management strategies at initiation of DMF treatment appear to reduce the burden of GI events, and a variety of GI management strategies may improve DMF persistence. Trial Registration: NCT02776072. Funding: Biogen (Cambridge, MA, USA).",
keywords = "Gastrointestinal events, Multiple sclerosis, Retrospective study, Tecfidera",
author = "Jinny Min and Stanley Cohan and Enrique Alvarez and Jacob Sloane and Phillips, {J. Theodore} and {van der Walt}, Anneke and Irene Koulinska and Fang Fang and Catherine Miller and Andrew Chan",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s40120-019-0127-2",
language = "English",
volume = "8",
pages = "109--119",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer",
number = "1",

}

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis : Management Strategies to Improve Persistence on Treatment and Patient Outcomes. / Min, Jinny; Cohan, Stanley; Alvarez, Enrique; Sloane, Jacob; Phillips, J. Theodore; van der Walt, Anneke; Koulinska, Irene; Fang, Fang; Miller, Catherine; Chan, Andrew.

In: Neurology and Therapy, Vol. 8, No. 1, 01.06.2019, p. 109-119.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis

T2 - Management Strategies to Improve Persistence on Treatment and Patient Outcomes

AU - Min, Jinny

AU - Cohan, Stanley

AU - Alvarez, Enrique

AU - Sloane, Jacob

AU - Phillips, J. Theodore

AU - van der Walt, Anneke

AU - Koulinska, Irene

AU - Fang, Fang

AU - Miller, Catherine

AU - Chan, Andrew

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. Methods: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072). GI management strategies were assessed via a study site questionnaire. Discontinuation rates were analyzed according to counseling patterns. Results: Of 826 DMF-treated patients at 66 sites, 809 from 65 sites were eligible for the GI analysis; of these, 27% experienced GI AEs. Within 1 year of treatment, 14% (118/826) of patients discontinued DMF, 5% (44/809) due to GI events. Most sites (92%) reported that patients were very likely (> 75% of the time) to be counseled about GI events at/before DMF treatment initiation and/or to be recommended that DMF be taken with food (86%); 48% of sites reported to be very likely to recommend using symptomatic therapies for GI AEs. Lower discontinuation rates were reported at sites very likely versus not very likely (≤ 75% of the time) to (1) provide counseling; (2) provide specific details regarding GI events; or (3) recommend taking DMF with food, and/or using symptomatic GI therapies. Conclusion: Counseling and other GI management strategies at initiation of DMF treatment appear to reduce the burden of GI events, and a variety of GI management strategies may improve DMF persistence. Trial Registration: NCT02776072. Funding: Biogen (Cambridge, MA, USA).

AB - Introduction: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. Methods: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072). GI management strategies were assessed via a study site questionnaire. Discontinuation rates were analyzed according to counseling patterns. Results: Of 826 DMF-treated patients at 66 sites, 809 from 65 sites were eligible for the GI analysis; of these, 27% experienced GI AEs. Within 1 year of treatment, 14% (118/826) of patients discontinued DMF, 5% (44/809) due to GI events. Most sites (92%) reported that patients were very likely (> 75% of the time) to be counseled about GI events at/before DMF treatment initiation and/or to be recommended that DMF be taken with food (86%); 48% of sites reported to be very likely to recommend using symptomatic therapies for GI AEs. Lower discontinuation rates were reported at sites very likely versus not very likely (≤ 75% of the time) to (1) provide counseling; (2) provide specific details regarding GI events; or (3) recommend taking DMF with food, and/or using symptomatic GI therapies. Conclusion: Counseling and other GI management strategies at initiation of DMF treatment appear to reduce the burden of GI events, and a variety of GI management strategies may improve DMF persistence. Trial Registration: NCT02776072. Funding: Biogen (Cambridge, MA, USA).

KW - Gastrointestinal events

KW - Multiple sclerosis

KW - Retrospective study

KW - Tecfidera

UR - http://www.scopus.com/inward/record.url?scp=85066320875&partnerID=8YFLogxK

U2 - 10.1007/s40120-019-0127-2

DO - 10.1007/s40120-019-0127-2

M3 - Article

AN - SCOPUS:85066320875

VL - 8

SP - 109

EP - 119

JO - Neurology and Therapy

JF - Neurology and Therapy

SN - 2193-8253

IS - 1

ER -